Opioid use disorder diagnoses spike among commercially insured Americans

Commercially insured patients with diagnoses of opioid use disorder increased 32.7 percent nationally from 2022 to 2025, according to FAIR Health's Opioid Tracker. In 2022, there were 449 patients with opioid use disorder diagnoses per 100,000 patients, while in 2025, there were 596. This and other findings were reported today when FAIR Health released its annual update of the Opioid Tracker, a free, interactive tool tracking opioid use disorder among commercially insured patients nationally and state by state. A brief released simultaneously offers a user's guide to the Opioid Tracker.

The Opioid Tracker includes a heat map representing patients with opioid use disorder diagnoses per 100,000 patients receiving medical services in 2025 for each state. Clicking on a state displays an infographic for that state with opioid use disorder data from 2025. The infographic includes the top five procedure code categories by utilization, the top five procedure codes by aggregate allowed amounts, the change in the number of patients with opioid use disorder diagnoses per 100,000 patients from 2022 to 2025, and the distribution of patients by age and gender. There is also a similar infographic for the nation as a whole, along with a second national infographic showing the top five states for opioid use disorder diagnoses, the fastest-growing specialties, the distribution of places of service, and service type (professional versus facility) as a percentage of total allowed amounts. The source of the data is FAIR Health's repository of commercial health claims.

Among the key findings revealed by the Opioid Tracker:

In 2025, Tennessee had the highest rate of commercially insured patients receiving treatment for opioid use disorder, with 1,551 patients with such a diagnosis per 100,000 patients (compared to 596 patients per 100,000 nationally). It was followed by West Virginia (1,528 patients), Mississippi (1,373 patients), Arkansas (1,320 patients) and Delaware (1,256 patients).

Nationally in 2025, alcohol/substance abuse services and treatments constituted the procedure code category with the highest utilization for opioid use disorder among commercially insured patients, representing 39.0 percent of all claim lines with an opioid use disorder diagnosis.

Nationally in 2025, G2067 (medication-assisted treatment, methadone, weekly bundle) was the procedure code with the highest aggregate allowed amount for opioid use disorder among commercially insured patients, accounting for 9.4 percent of aggregate allowed amounts for that diagnosis. The average allowed amount for this code was $243.

The highest percentage of opioid use disorder diagnoses among commercially insured patients were attributable to patients in the 41 to 50 age group, with 28.1 percent of the total age distribution in 2025 across the nation.

Among commercially insured patients with opioid use disorder diagnoses nationally in 2025, males were 56.1 percent of patients with those diagnoses, while females were 43.9 percent.

The fastest-growing specialty involved in the treatment of opioid use disorder nationally in 2025 was nurse practitioner, which increased 67 percent in percent of claim lines from 2022 to 2025. In second and third positions, respectively, were psychiatric nurse (47 percent) and emergency medicine (44 percent).